Lindsey Shapiro, PhD, science writer —

Intranasal, or into-the-nose, delivery of foralumab, an investigational antibody-based treatment being developed by Tiziana Life Sciences, restored the activity of microglial cells and improved cognition in a mouse model of Alzheimer’s disease. Formerly known as NI-0401, foralumab acts to lower inflammation by blocking the activity of CD3, a protein…

Buntanetap, an experimental treatment for neurodegenerative diseases, was safe, lowered toxic protein accumulation, reduced inflammation, and improved cognition in people with Alzheimer’s disease. This was according to data from a Phase 2a trial (NCT04524351) that evaluated the investigational therapy against a placebo…

Treatment with Alzheon‘s oral candidate ALZ-801 (valiltramiprosate) lowered levels of a key biomarker for Alzheimer’s disease — and led to significant memory improvements in people with the neurodegenerative disorder. That’s according to data from a six-month interim analysis of an ongoing Phase 2 biomarker…

Chronic treatment with HT-ALZ, Hoth Therapeutics‘ investigational oral therapy for Alzheimer’s disease, led to significant cognitive improvements in a mouse model of the neurodegenerative condition. The data were collected as part of Hoth’s ongoing sponsored research agreement with investigators at Washington University in St. Louis, Missouri, led by…

The first patient has been dosed in an open-label dose optimization trial of bryostatin, an investigational treatment for Alzheimer’s disease. According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Amyloid Plasma Panel, Roche’s blood-based biomarker test designed to enable earlier Alzheimer’s disease diagnoses. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening…

Repeated dosing of ACD856, an investigational therapy for Alzheimer’s disease, was generally safe and well tolerated in healthy adult volunteers, according to data from a now-completed Phase 1 trial. AlzeCure Pharma is developing ACD856 as its lead therapeutic candidate in the company’s NeuroRestore platform, which contains investigational therapies for…

C2N Diagnostics has developed a new assay that precisely measures blood levels of four forms of tau, a protein involved in the brain changes observed in Alzheimer’s disease. Called the plasma tau multianalyte assay (p-tau MAA), the test is intended to be used for research purposes only and…

An investigational gamma-secretase modulator designed for the treatment of Alzheimer’s disease led to an efficient and long-lasting reduction of toxic amyloid-beta 42 peptide in cell cultures and mouse brain cells, according to data from a recent study. In mice, the compound, called AC-0027875, was also able to penetrate the…

The therapeutic candidate allopregnanolone is safe and well-tolerated in people with early Alzheimer’s disease, according to data from a Phase 1b/2a clinical trial that also investigated the medication’s maximum-tolerated dose. Moreover, MRI scans showed that allopregnanolone — dubbed ALLO by researchers — may protect against brain tissue loss…